Spyre Therapeutics, Inc. (NASDAQ: SYRE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $45.00 price target on the stock.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody [Yahoo! Finance]
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody